Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodayPrecious Metals
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNewSmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
SMS Lifesciences India
Small Cap•574 Employees•IPO 2017
Current Price
₹1380.10
26.6 (1.97%)Updated
Today's Range
1338
₹1380.10
1430
52 Week Range
52W Low₹1067.00
52W High₹1539.00
₹1380.10
Downside29.34%
Upside11.51%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹407.77 Cr
Market Cap
Total market value of companyP/E Ratio
23.61
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
1.66
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹57.12
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
3.98%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
11.80%
ROCE
Return on Capital Employed. >15% is goodNet Margin
5.16%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
14.41%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
5.74%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.44
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹650.15
Book Value
Net asset value per shareDividend Yield
0.11%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
0.00%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Strong promoter confidence evidenced by increased holding to 71.40% by March 2025.
- •P/E ratio of 19.10 is slightly below sector average, suggesting potential undervaluation.
Weaknesses
5 points- •Latest quarterly net profit declined significantly by 49.66%, raising profitability concerns.
- •Extremely low Return on Equity (3.98%) indicates poor efficiency in capital utilization.
Opportunities
5 points- •Increasing global healthcare spending and demand for generic drugs present growth avenues.
- •Robust growth in broader healthcare sector offers market expansion and diversification.
Threats
5 points- •Highly competitive pharmaceutical industry with larger, established players poses market share risk.
- •Stringent and evolving regulatory frameworks can increase compliance costs and delay approvals.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
TV Praveen | 18 Mar 2025 | 19 Mar 2025 | 2.53 L | 1.21 L | ₹1,062.15 | BUY |
T V V S N MURTHY (HUF) | 18 Mar 2025 | 19 Mar 2025 | - | 2.41 L | ₹1,062.15 | SELL |
Sudeepthi Gopineedi | 18 Mar 2025 | 19 Mar 2025 | 1.99 L | 1.21 L | ₹1,062.15 | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1611.40 | +₹231.30 | +16.76% |
| R3 | ₹1519.40 | +₹139.30 | +10.09% |
| R2 | ₹1474.70 | +₹94.60 | +6.85% |
| R1 | ₹1427.40 | +₹47.30 | +3.43% |
| PIVOT | ₹1382.70 | 2.60 | 0.19% |
| CURRENT | ₹1380.10 | - | - |
| S1 | ₹1151.40 | -₹228.70 | -16.57% |
| S2 | ₹1243.40 | -₹136.70 | -9.91% |
| S3 | ₹1290.70 | -₹89.40 | -6.48% |
| S4 | ₹1335.40 | -₹44.70 | -3.24% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+19.1% vs avg
0.04L
(25 Nov 2025)Delivery %-2.1% vs avg
71.4%
(25 Nov 2025)Avg Volume (20D)20-day average
0.03L
(28 Oct - 25 Nov)Avg Delivery %Trend ↓
73.5%
(28 Oct - 25 Nov)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Valiant Laboratories Ltd
457.00 %
Highest Dividend Yield
Sun Pharmaceutical Industries Ltd
0.91 %
Peer Comparison
| Company Name |
|---|
 Bafna Pharmaceuticals Ltd |
 Lyka Labs Ltd |
 Medico Remedies Ltd |
 Nectar Lifescience Ltd |
 Sun Pharmaceutical Industries Ltd |
 Valiant Laboratories Ltd |
 Zim Laboratories Ltd |
About
SMS Lifesciences India Ltd
SMS Lifesciences India Limited is a prominent Indian manufacturer and exporter of active pharmaceutical ingredients (APIs) and intermediates. Their business model centers around supplying crucial components used in the production of various pharmaceutical drugs, playing a significant role in the global pharmaceutical supply chain. The company has established a considerable presence within the Indian market and actively participates in international trade.
The company's product portfolio spans a wide range of therapeutic areas. They produce APIs for treatments addressing diverse medical conditions, including ulcers, erectile dysfunction, gout, infections, obesity, fungal infections, convulsions, nausea, ophthalmic issues, parasitic infestations, and more. This breadth of therapeutic applications demonstrates their versatility and capacity within the API market. Beyond their existing API offerings, SMS Lifesciences is actively engaged in research and development, focusing on expanding their capabilities into areas such as antidepressants, antipsychotics, antihypertensives, veterinary pharmaceuticals, antivirals, and anticoagulants.
In addition to APIs, SMS Lifesciences manufactures and supplies intermediates, which are the precursor chemicals used in the synthesis of APIs. The range of intermediates they offer mirrors the diversity found in their API portfolio, supporting the production of medications for similar therapeutic areas. This integrated approach, encompassing both APIs and intermediates, allows for greater control over the supply chain and potential cost efficiencies.
Established in 1990 and headquartered in Hyderabad, India, SMS Lifesciences has cultivated a significant amount of experience in the pharmaceutical industry. Their commitment to research and development, alongside their diversified product offerings, positions them for continued growth and expansion within the competitive global API market. Their export activities highlight their ambition to serve a wider international customer base and contribute to global healthcare.
COMPANY FACTS - SMSLIFE
Registered Address
Plot No:19-III, Road No:71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills
Hyderabad
TELANGANA
IN
Tel: 914066288888
Website:https://www.smslife.in/
Investor Relations:https://www.smslife.in/financials.php
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 574
IPO Date: 17/08/2017
Investor Questions Answered
SMS Lifesciences India Ltd (SMSLIFE) Stock FAQs
Get answers to the most common questions about SMS Lifesciences India Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of SMS Lifesciences India Ltd (SMSLIFE) is ₹1,380.1. Today, the stock has gained by ₹26.60 (1.97%), trading in a range of ₹1,338 to ₹1,430. The stock opened at ₹1,384 with a trading volume of 3,713 shares.
SMS Lifesciences India Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹407.77 crores, P/E ratio of 23.61, ROE of 3.98%, and ROCE of 11.80%. The dividend yield stands at 0.11%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of SMS Lifesciences India Ltd (SMSLIFE) is ₹1,539, while the 52-week low is ₹1,067. Currently trading at ₹1,380.1, the stock is 66.3% away from its 52-week low and 10.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy SMS Lifesciences India Ltd stock at ₹1,380.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 23.61 and P/B ratio of N/A. Today's performance shows a gain of 1.97%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
SMS Lifesciences India Ltd offers a dividend yield of 0.11%, which means for every ₹100 invested at the current price of ₹1,380.1, you can expect to receive approximately ₹0.11 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
SMS Lifesciences India Ltd's key financial metrics include: P/E Ratio: 23.61, P/B Ratio: N/A, ROE: 3.98%, ROCE: 11.80%, Dividend Yield: 0.11%, EPS: ₹57.12, Book Value: ₹650.15, Debt-to-Equity: 0.44, and Current Ratio: N/A. The company's market cap stands at ₹407.77 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
SMS Lifesciences India Ltd stock opened at ₹1,384 and is currently trading at ₹1,380.1, showing a gain of ₹26.60 (1.97%). The intraday high is ₹1,430 and low is ₹1,338. The trading volume stands at 3,713 shares, indicating moderate market participation today.
SMS Lifesciences India Ltd has a Price-to-Earnings (P/E) ratio of 23.61, which means investors are willing to pay ₹23.61 for every ₹1 of earnings. With an EPS of ₹57.12, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
SMS Lifesciences India Ltd has a market capitalization of ₹407.77 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,380.1) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
SMS Lifesciences India Ltd has a book value of ₹650.15 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,380.1, which is 112.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
SMS Lifesciences India Ltd has a Return on Equity (ROE) of 3.98% and Return on Capital Employed (ROCE) of 11.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
SMS Lifesciences India Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
SMS Lifesciences India Ltd has a debt-to-equity ratio of 0.44, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
SMS Lifesciences India Ltd has an Earnings Per Share (EPS) of ₹57.12, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,380.1 and P/E ratio of 23.61, investors are paying 23.61 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
SMS Lifesciences India Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
SMS Lifesciences India Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze SMS Lifesciences India Ltd stock, consider: 1) Fundamental Analysis - Review P/E (23.61), ROE (3.98%), debt-to-equity (0.44), and growth rates. 2) Technical Analysis - Check 52-week range (₹1067.00 - ₹1539.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1380.10) with book value (₹650.15) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of SMS Lifesciences India Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,380.1 is 13701x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in SMS Lifesciences India Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1067.00 - ₹1539.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.44 indicates leverage. 4) Liquidity Risk - Based on trading volume of 3,713 shares. 5) Valuation Risk - P/E of 23.61 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
SMS Lifesciences India Ltd operates in the industry with key metrics: P/E ratio of 23.61, ROE of 3.98%, market cap of ₹407.77 crores, and dividend yield of 0.11%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.44), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for SMS Lifesciences India Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,380.1, with a 52-week range of ₹1067.00 to ₹1539.00. Based on fundamentals like P/E (23.61), ROE (3.98%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling SMS Lifesciences India Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1380.10. 2) Fundamental Deterioration - Declining ROE (currently 3.98%), increasing debt (D/E: 0.44), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for SMS Lifesciences India Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.11%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu